story of the week
Safety Analysis of Sacituzumab Govitecan in Metastatic TNBC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
NPJ breast cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer
NPJ Breast Cancer 2022 Aug 29;8(1)98, HS Rugo, SM Tolaney, D Loirat, K Punie, A Bardia, SA Hurvitz, J O'Shaughnessy, J Cortés, V Diéras, LA Carey, L Gianni, MJ Piccart, S Loibl, DM Goldenberg, Q Hong, M Olivo, LM Itri, K KalinskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.